Eyenovia(EYEN) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for analysis in Q4 Commenced sales activities with focus on Mydcombi in 260+ of ices and preparations for launch of clobetasol propionate ophthalmic susp ...